Immunotherapy is emerging as the newest pillar of cancer treatment, with the potential to assume a place alongside surgical debulking, radiation therapy, and chemotherapy. Early experiences with antitumor vaccines demonstrated the feasibility and potential efficacy of this approach and newer agents, such as immune checkpoint blocking antibodies and modern vaccine platforms, have ushered in a new era. These efforts are headlined by work in melanoma, prostate cancer, and renal cell carcinoma; however, substantial progress has been achieved in a variety of other cancers, including high-grade gliomas. A recurrent theme of this work is that immunotherapy is not a one-size-fits-all solution. Rather, dynamic, tumor-specific interactions within the tumor microenvironment continually shape the immunologic balance between tumor elimination and escape. High-grade gliomas are a particularly fascinating example. These aggressive, universally fatal tumors are highly resistant to radiation and chemotherapy and inevitably recur after surgical resection. Located in the immune-privileged central nervous system, high-grade gliomas also employ an array of defenses that serve as direct impediments to immune attack. Despite these challenges, vaccines have shown activity against high-grade gliomas and anecdotal, preclinical, and early clinical data bolster the notion that durable remission is possible with immunotherapy.
Introduction
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, with an incidence of 2-3 per 100,000 (1) . Despite recent advances in chemotherapy, radiation therapy, and surgical resection, GBM remains a devastating diagnosis with a median survival of 14.6 months despite surgical resection, radiation therapy and temozolomide (2) . While GBM exploits many of the same molecular pathways that drive aggressive behavior in other solid tumors, several characteristics of GBM deserve special consideration. In most solid tumors, metastasis is a sentinel event in cancer progression and a frequent harbinger of incurable disease. Multifocal GBM, however, is atypical in that it remains unclear whether a multifocal disease pattern represents disease spread or recurrent de novo tumor development. Furthermore, metastasis outside the CNS has been reported (3), but is infrequent and not a primary cause of morbidity and mortality.
Despite the ability to reliably achieve gross total resection with modern surgical techniques, neoplastic infiltration beyond the radiographically defined tumor margins leads to inevitable recurrence. Adjuvant therapy with radiation and alkylating chemotherapeutic agents, such as temozolomide and carmustine (2, 4) , may delay disease progression, but outgrowth of resistant clones limits response durability. Mechanisms underlying resistance to radiochemotherapy are a topic of intense investigation with attention particularly focused on glioma stem cells (5) , which are characteristically enriched for activity of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) (6) , and have demonstrated resistance to alkylating agents (7) and ionizing radiation (8) . In addition, glioma stem cells are remarkably malleable, as illustrated by the finding that this cell population can differentiate into pericytes and vascular endothelium as well as to bulk tumor cells (9, 10) . Such plasticity also potentiates the characteristic heterogeneity reflected in the distinction "multiforme" (11) . Accordingly, recent work has parsed high-grade gliomas into subclasses (12) and identified molecular profiles, such as isocitrate dehydrogenase mutations (IDH1/IDH2) (13) , MGMT methylation status (14) , and Author Manuscript Published OnlineFirst on April 25, 2014 ; DOI: 10.1158/1078-0432.CCR- epithelial growth factor receptor (EGFR) amplification (12) with clear prognostic significance.
Even these more discriminating classification schemes, however, are incomplete as they fail to account for intratumoral heterogeneity, which may present an even more significant therapeutic challenge (15) . One strategy for circumventing the lack of a clearly targetable molecular signature is to intervene in a process that is presumably critical to all cells comprising the tumor mass, such as angiogenesis. However, GBM cells have demonstrated a remarkable capacity to escape angiogenesis inhibitors through several mechanisms, including enhanced migratory behavior via upregulation of matrix metalloproteinases (16) .
Immunotherapy has recently emerged into the clinical mainstream with the approval of the first antigen-specific agent, sipuleucel-T, for castrate-resistant prostate cancer in 2010 (17) , and the approval of an immune checkpoint inhibitor, ipilimumab, for metastatic melanoma in 2011 (18) . Historically, immunotherapy for GBM has afforded valuable insights, but failed to generate comparable clinical results to melanoma, renal cell carcinoma, and prostate cancer.
There are several fundamental reasons for this discrepancy. Unlike prostate cancer, which expresses reasonably well-characterized tumor-restricted antigens, and melanoma, which is clearly immunogenic, GBM expresses relatively few known tumor-restricted antigens and has been classically considered non-immunogenic (19) . These characteristics, coupled with location in the immunologically privileged brain--which is, in turn, confined within the edema intolerant cranial vault--have likely tempered enthusiasm for the application of immunotherapy to GBM.
Yet, recent successes indicate that immunotherapy for GBM may be effective and well tolerated, with several immunotherapy regimens currently in Phase II and Phase III clinical trials.
Redefining CNS Immune Privilege
Classification of the CNS as an immunologically privileged site originated with the observation that tissues engrafted into the brains of experimental animals were rejected more slowly than tissues transplanted to other sites (20) . Subsequent work characterizing the blood- Author Manuscript Published OnlineFirst on April 25, 2014; DOI: 10.1158/1078-0432.CCR- to reach the cervical lymph nodes (27) . The relative role of each of these routes in tumor antigen presentation is unknown and deserves further study. Once an antigen reaches the cervical lymph nodes, however, it is likely that immune responses to CNS antigens may be constrained by the same mechanisms associated with mucosal tolerance induction, including TGF-β production by T regulatory cells (28) , production of antibodies that signal through inhibitory Fc receptors like CD32 (FcRIIB) (29), and preferential presentation in germinal centers, resulting in skewing toward B-cell predominant responses (30) .
Microglia, the resident tissue macrophages of the CNS, are a particularly important component of this system. Microglia are of myeloid origin and migrate to the brain during development, but are phenotypically distinct from macrophages in peripheral tissues (31) . The interplay between peripheral and local myeloid cell populations is illustrated by the finding that circulating monocytes readily repopulate the microglia niche in CD11b-herpes simplex virus thymidine kinase (CD11b-HSVTK) transgenic mice receiving intraventricular injection of ganciclovir (32) . However, resident microglia are confined to the CNS, and whether cells that express dendritic cell markers and originate in the CNS have access to peripheral tissues remains a focus of investigation (33) . In addition to their prominent role in innate immunity, which is reviewed in detail elsewhere (34) , microglia play a crucial, albeit more nebulous role in adaptive immunity by re-presenting antigen to activated lymphocytes, a critical process for preventing deletion of lymphocytes that enter the brain parenchyma (31) . Microglia may work in concert with local dendritic cells, which migrate in from the peripheral circulation and are also found in the meninges and choroid plexus (35) , although the relative contributions of resident and migrating APCs in shaping the adaptive immune response is another aspect of CNS immunology that is poorly understood. In summary, CNS antigens may be presented in draining lymph nodes, trials. An early feasibility study by Sampson (Table 1) .
Immune Checkpoints: Objective Anti-Tumor Responses in Multiple Cancers
Multiple mechanisms exist to protect healthy tissues against autoimmunity. In the earliest stages of lymphocyte development, TCRs that bind autoantigens are deleted in the process of Other immune checkpoints that are being investigated for clinical translation include Lymphocyte activation gene-3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3). LAG-3 is a CD4 homolog that binds MHC class II (74) and appears to play a role in controlling expansion of previously activated T cells rather than independent modulation of T cell activity (75) . This hypothesis has been borne out in preclinical models (76) . TIM-3 is a glycoprotein with extracellular immunoglobulin and mucin domains that binds Galectin-9. Like LAG-3, TIM-3 appears to be principally involved in fine-tuning ongoing immune responses (77) .
Combination Immunotherapy
Studies in checkpoint signaling illustrate a general tenet of immune tolerance: it is generated, maintained, and refined by multiple overlapping, yet non-redundant pathways, which operate in distinct anatomic and physiologic compartments. A striking clinical example comes from a recent clinical trial combining nivolumab and ipilimumab in patients with metastatic melanoma (78) . The authors reported greater than 80% reduction in tumor burden in 53% of patients, albeit with a toxicity profile somewhat more pronounced than that observed using ipilimumab monotherapy. Furthermore, recent work by our group suggests that synergistic responses may be achieved by combing immunotherapy with radiation therapy in a glioma model (79) . Several other candidate combinatorial strategies are being evaluated, and accumulating data suggest that intervention at multiple levels of the immune response will be required to achieve maximum antitumor activity.
Research. We suspect that a combination immunotherapy regimen will be required to achieve meaningful responses in GBM. Specifically, such a regimen would involve activation of a systemic tumor antigen-directed response in addition to combinatorial checkpoint blockade and manipulation of the tumor microenvironment. Our focus on vaccines and checkpoint inhibitors in this review reflects an illustrative, though by no means exclusive, means of translating this strategy. This notion is supported by work in other tumors. GVAX has been safely administered in combination with CTLA-4 blockade (80), a combination which has demonstrated efficacy in preclinical models (65, 81) and combining GVAX with PD-1 blockade has been similarly promising (82) . Although listeria vaccines are only beginning to be applied to GBM, this vaccine platform may prove particularly advantageous for combinatorial therapy as listeria vaccines can drive T cell proliferation without PD-1 up-regulation (83) and increase T effector to T regulatory cell ratios in the brain tumor microenvironment (Jackson, Lim, and Drake, unpublished data). In the process of translating these findings to a combinatorial clinical regimen, it should be noted that intracranial tumors might respond differently to listeria vaccination than peripheral tumors (84). Additional data from our group indicate that myeloid cells in the brain tumor microenvironment may modulate systemic immunologic responses to brain tumor-associated antigens differently than myeloid cells associated with otherwise equivalent non-CNS tumors (Jackson, Lim, and Drake, unpublished data). Taken together, these concepts reinforce the status of the CNS as a unique immunologic compartment, which mandates special considerations for GBM immunotherapy.
Conclusions
GBM remains a devastating clinical diagnosis and significant scientific challenge.
Effectively developing immunotherapy against GBM will require combinatorial strategies that target multiple levels of immune tolerance. These efforts will likely be guided by successes in other tumors, but the unique aspects of GBM pathology must remain at the forefront. Many 
